Tab. VI.
Appraisal phase.
| Normalised score of the domains | Prioritisation | Final result | |||
|---|---|---|---|---|---|
| Domains | Baseline scenario | Introduction of PrEP | Baseline scenario | Introduction of PrEP | |
| Health problem and current use of technology | 0.471 | 0.529 | 0.044 | 0.021 | 0.024 |
| Description and technical characteristics | 0.500 | 0.500 | 0.022 | 0.011 | 0.011 |
| Safety | 0.438 | 0.563 | 0.178 | 0.078 | 0.100 |
| Clinical effectiveness | 0.545 | 0.455 | 0.200 | 0.109 | 0.091 |
| Cost and economic evaluation | 0.611 | 0.389 | 0.133 | 0.081 | 0.052 |
| Ethical analysis | 0.625 | 0.375 | 0.089 | 0.056 | 0.033 |
| Social aspects | 0.485 | 0.515 | 0.156 | 0.075 | 0.080 |
| Legal aspects | 0.375 | 0.625 | 0.067 | 0.025 | 0.042 |
| Organisational aspects | 0.538 | 0.462 | 0.111 | 0.060 | 0.051 |
| Total | 4.588 | 4.412 | 0.516 | 0.484 | |